Analysis and reporting of Oncology trials is getting more complex day-by-day due to the varying mechanism of action introduced by novel anti-cancer agents, thus challenging the researchers to reconsider whether the conventional efficacy and safety analyses as well as trial designs adequately address these new mechanisms under study. Therefore, the focus of this session is to share the different intricacies of Oncology trials and how statisticians and programmers can contribute in the development of innovative cancer drugs.